Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]Ac-mcp-SC16
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[225Ac]Ac-mcp-SC16 is a targeted alpha therapy (TAT) radiopharmaceutical designed for the treatment of neuroendocrine malignancies. It consists of the alpha-emitting radioisotope actinium-225 (225Ac) conjugated to the SC16.56 monoclonal antibody via a macropa-derived (mcp) chelator. The antibody component, SC16.56, specifically targets Delta-like protein 3 (DLL3), a protein frequently overexpressed on the surface of small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC) cells. By delivering high-LET (linear energy transfer) alpha radiation directly to DLL3-expressing cells, the agent induces lethal double-strand DNA breaks while minimizing damage to surrounding healthy tissue. Preclinical data indicates significant antitumor activity, although some renal and ovarian toxicity has been noted in comparative studies.
- Other names
- Actinium-225-mcp-SC16Actinium225-mcp-SC16Actinium 225-mcp-SC16
02
Targets
DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on [225Ac]Ac-mcp-SC16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [225Ac]Ac-mcp-SC16.